Impact of COVID-19 on mucormycosis presentation and laboratory values: A comparative analysis

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(5), P. e0321897 - e0321897

Published: May 2, 2025

Background The COVID-19 pandemic has led to an alarming increase in mucormycosis coinfections and its rapid progression. overlapping risk factors symptoms between further complicate prompt detection, which is crucial for patient survival. This study aims investigate potential differences progression, initial symptom presentation, laboratory value alterations patients with history enhance diagnostic accuracy improve outcomes this complex clinical scenario. Methodology retrospective cohort study, conducted from April 1, 2021, March 31, 2022, examined 102 diagnosed at two primary teaching hospitals. Patients were categorized into groups based on history. Variables included demographic information, parameters, results, outcomes. compared studies presentation history-positive history-negative groups, a particular focus mortality rates associated comorbidities such as diabetes, cancer immunosuppressive treatment. Results Initial presentations differed significantly, eneralized Estimating Equations (GEE) analysis, adjusted comorbidities, revealed was increased platelet counts (P = 0.0311) decreased facial swelling 0.049) fever reporting < 0.001). Cancer history, treatment also showed significant associations various parameters. Laboratory analysis without group lower WBC 0.002), higher hemoglobin levels 0.001) controls. Diabetes more prevalent patients, while common Conclusion reveals intricate relationships mucormycosis, challenging earlier findings. Mucormycosis exhibited altered presentation. research highlights varied patterns across subgroups underscores the complexity of interactions COVID-19, cancer, diabetes cases. These findings advocate multivariate analytical approaches better understand these multifaceted relationships.

Language: Английский

Bioinformatics and system biology approach to discover the common pathogenetic processes between COVID-19 and chronic hepatitis B

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(5), P. e0323708 - e0323708

Published: May 23, 2025

Introduction The ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome 2 (SARS-CoV-2), presents a significant global public health threat. Concurrently, hepatitis B virus (HBV) remains challenge. While previous studies have indicated an association between COVID-19 and chronic B, common underlying pathogenesis of these diseases incompletely understood. Methods To investigate shared molecular mechanisms HBV infection COVID-19, comprehensive investigation was conducted using bioinformatics systems biology. Specifically, we utilized RNA-seq datasets (GSE196822 GSE83148) to identify differentially expressed genes (DEGs) associated with both SARS-CoV-2 infection. Subsequently, DEGs were pathways, hub genes, transcriptional regulatory networks, potential drugs. differential expression in verified GSE171110 GSE94660 datasets, respectively. Results From 106 identified, immune-related pathways found play role development progression COVID-19. Protein-protein interaction (PPI) network analysis revealed 8 genes: CDK1 , E2F7 E2F8 TYMS KIF20A CENPE TPX2 HMMR CD8A GZMA . In validation set, statistically group compared healthy control group. Transcriptional identified 155 microRNAs (miRNAs) 43 transcription factors (TFs) as signals. Notably, therapeutic drugs for including progesterone, estradiol, dasatinib, aspirin, etoposide, irinotecan hydrochloride, phorbol 12-myristate 13-acetate, lucanthone, calcitriol. Conclusion This research elucidates targets, signaling promising small molecule compounds that could aid treatment

Language: Английский